MTF recently completed a multi-center, prospective, randomized, controlled clinical trial evaluating the use of AlloPatch Pliable in Chronic Diabetic Foot Ulcer (DFU) applications. As an advanced treatment option, AlloPatch Pliable significantly outperformed the use of standard of care (SOC) alone. But, don’t just take our word for it, check out the stats.

MTF Wound Care | 125 May Street, Edison NJ 08837 USA | (800) 946-9008 | +1 (732) 661-0202 | mtfwoundcare.org
A fraction of the cost of other options

88% more cost effective than Dermagraft®

83% more cost effective than Apligraf®

47% more cost effective than EpiFix®

Faster healing rates and fewer treatments

~1/2 the time to closure

Not only did AlloPatch Pliable + SOC heal more wounds, it did so faster. On average, AlloPatch Pliable + SOC can save up to 4 dressings as opposed to SOC Alone.

The average wound size in the AlloPatch Pliable DFU study was 4.7cm², the largest of any similar prospective 12 week DFU study. Bigger wounds and faster healing.

Dermagraft® is a registered trademark of Organogenesis, Inc.
Apligraf® is a registered trademark of Novartis.
EpiFix® is a registered trademark of MiMedx Group, Inc.
AlloPatch® is a registered trademark of MTF.
MTF Wound Care® and MAKING WOUND CARE BETTER, FOR EVERYONE® are registered trademarks of MTF.
© The Musculoskeletal Transplant Foundation. All rights reserved.